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Abstract The synthesis of proliferating cell nuclear antigen
(PCNA) is strictly regulated during the cell cycle. To investigate
the contribution of the promoter region to the up-regulation of
human PCNA expression at the onset of S phase, we have
examined 17 putative elements with reporter assays in quiescent
L-O2 cells and following serum stimulation. The E2F-like se-
quence 5P-TTCCCCGCAA-3P located at 384 to 375 is re-
quired for the serum-induced transactivation. In electrophoretic
mobility shift assays, nuclear extracts from asynchronous L-O2
cells exhibit two binding activities toward the 375 E2F oligo-
nucleotide, and the minor band, whose formation could be in-
terfered with by E2F-1 antibody, represents an S phase-speci¢c
complex. This is the ¢rst demonstration of the E2F site in the
human PCNA 5P promoter as a serum-responsive element.
2 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The proliferating cell nuclear antigen (PCNA) was ¢rst de-
scribed by Miyachi et al. [1] as a nuclear antigen restricted to
proliferating cells that reacts with sera from some patients
with the autoimmune disorder systemic lupus erythematosus.
It has been well described that PCNA forms a sliding homo-
trimeric clamp around DNA and functions as a DNA poly-
merase processivity factor during replication [2] and repair [3].
Through its multiple protein^protein interactions, PCNA co-
ordinates events in replication, epigenetic inheritance, repair,
and cell cycle control [4]. Therefore it is important to under-
stand the regulation of PCNA expression and the functions of
PCNA within the cell cycle.
PCNA synthesis is strictly regulated during the cell cycle,
with a clear increase at the G1/S transition. It is evident that
PCNA represents a key protein necessary for the transition of
cells from quiescence to S phase [5^7]. The full activity of the
human PCNA (hPCNA) promoter was shown to be approx-
imately within the 210 bp upstream of the transcription start
site [8], and the ATF/CRE site (nucleotide 352 to 345) is
crucial to both basal transcription and E1A-driven transacti-
vation [9,10]. It had been reported that the 5P promoter may
not be involved in the serum-dependent growth regulation of
the hPCNA gene in murine 3T3 cells [11]. Thus, subsequent
investigations of the cell cycle regulatory elements focused on
the introns [12,13], and the E2F site located in the ¢rst intron
at position +583 was found to play a positive role in hPCNA
transactivation at the onset of S phase [14].
In our previous work, to achieve a complete overview of the
hPCNA promoter, we searched the region from 3538 to +60
relative to the transcription start site for potential cis-ele-
ments, and recognized 17 putative targets (summarized in Ta-
ble 1). Transient expression assays in di¡erent cell lines dem-
onstrated that besides the ATF/CRE site detected by Morris
and Mathews [9], an E2F site (nucleotides 386 to 375), a
CTF site (nucleotides 399 to 395), and an SP1 site (nucleo-
tides 3191 to 3186) are likely general cis-elements [15]. In
this study, to comprehensively assess the individual contribu-
tion of every putative element to serum responsiveness, we
used transient expression assays in synchronous L-O2 cells
to analyze the activities of 17 mutant hPCNA promoters,
each bearing an 8 bp substitution in one of the 17 putative
elements. We found that the E2F site (nucleotide 386 to 375)
is required not only for optimal hPCNA promoter activity,
but also for the responsiveness to serum stimulation in L-O2
cells. We further characterized this regulatory element and
suggest a functional role of an E2F-1-containing complex as
an S phase-speci¢c positive regulator of hPCNA expression.
2. Materials and methods
2.1. Cell culture, synchronization and FACS analysis
The normal human hepatic cell line L-O2 was maintained in high
glucose Dulbecco’s modi¢ed Eagle’s medium (25 mM glucose; Gibco
BRL) supplemented with 10% fetal bovine serum (Gibco BRL), 100
U/ml penicillin, and 50 Wg/ml streptomycin under 5% (v/v) CO2 at
37‡C.
G0/G1 synchronization was obtained by inducing proliferation ar-
rest after serum starvation for 48 h; subsequent re-entry into the cell
division cycle was induced by adding fresh serum (15% ¢nal concen-
tration). Synchronous progression through S phase was obtained by
arresting the cells at the G1/S transition in the presence of hydroxy-
urea (1 mM ¢nal concentration for 24 h) and subsequently transfer-
ring the cells to hydroxyurea-free medium. Finally, cells were
synchronized in G2 in the presence of 0.2 Wg/ml nocodazole for
10 h; the block was released by transferring the cells to nocodazole-
free medium. All three types of synchronization were monitored by
£uorescence-activated cell sorting (FACS) analysis. At regular intervals
after the block release, cell samples were harvested in phosphate-bu¡-
ered saline, ¢xed in 70% (v/v) ethanol, and incubated with RNase A
(500 Wg/ml) for 1 h at 37‡C. Propidium iodide (100 Wg/ml cell sample)
was added and the DNA contents of cell samples were analyzed in a
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FACStar Plus cyto£uorometer (Becton Dickinson) with the Multi-
cycle software (10 000 events per sample).
2.2. Plasmids, transfection and luciferase assay
The plasmid pGL2-hPCNA carries the wild-type hPCNA promoter
spanning nucleotides 3538 to +60 relative to the transcription start
site, followed by the ¢re£y luciferase reporter sequence. Plasmids
P3509, P3498, P3342, P3330, P3289, P3216, P3199, P3186,
P3139, P3122, P394, P375, P364, P344, P318, P+10 and P+38,
constructed in our previous work [15], each have one of 17 di¡erent
8 bp substitutional mutations in potential promoter elements (Table
1). The control promoter construct pGL2-SV40 carries the cell cycle-
independent promoter of the SV40 early gene upstream of the Renilla
luciferase coding sequence. L-O2 cells were transfected with plasmids
using LipofectAMINE reagent (Invitrogen) according to the standard
protocol. Transfection experiments were performed on duplicate sets
of cultures, which were subjected to determination of luciferase activ-
ity and to FACS monitoring of the cycle progression. Luciferase as-
says were performed using the Promega Luciferase Assay Kit follow-
ing the manufacturer’s instructions. Activities of ¢re£y (experimental)
and Renilla (control) luciferases were measured in a luminometer BG-
P (MGM). Promoter strengths were quanti¢ed by calculating the ratio
of ¢re£y/Renilla luciferase activity of the same lysate sample.
2.3. Preparation of nuclear extracts
Nuclear extracts were prepared from asynchronous and synchro-
nous L-O2 cultures as described previously with some modi¢cation
[16]. 0.5^1U108 cells were collected, and washed several times with
phosphate-bu¡ered saline. Then the cell pellet was resuspended in ¢ve
volumes of ice-cold cell homogenization bu¡er (10 mM HEPES pH
7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.5 mM
phenylmethylsulfonyl £uoride) by gentle pipetting. The cells were al-
lowed to swell on ice for 10 min, and pelleted by centrifugation at
250Ug for 10 min. Then the pellet was resuspended in three volumes
of ice-cold cell homogenization bu¡er containing 0.05% NP-40, and
homogenized with 20 strokes of a tight-¢tting homogenizer. The ho-
mogenate was centrifuged at 250Ug for 10 min. The nuclear pellet
was resuspended in 1 ml of ice-cold cell resuspension bu¡er (40 mM
HEPES pH 7.9, 0.4 M KCl, 10% glycerol, 1 mM dithiothreitol,
0.1 mM phenylmethylsulfonyl £uoride, 0.1% aprotinin), and 5 M
NaCl was accurately added to a ¢nal concentration of 300 mM. After
the cells were placed on ice for 30 min, the nuclear extract was cen-
trifuged at 46 000Ug at 4‡C for 20 min and the supernatant was
frozen in aliquots at 370‡C. Protein concentration was quantitated
using the Bradford method.
2.4. Electrophoretic mobility shift assay
Brie£y, binding reactions were set up with 3^15 fmol of 5P-32P-
labeled oligonucleotide and 2^10 Wg of nuclear extract in 20 Wl of
reaction mixture containing 1 mM dithiothreitol, 1 mM EDTA,
0.2% Tween 20, 0.05 Wg/Wl poly(dI-dC), and 0.05 Wg/Wl poly-L-lysine.
The reaction was incubated at room temperature for 25 min. Com-
petition experiments were performed routinely. In interference experi-
ments, the nuclear extract was pre-incubated with E2F-1 antibody
(KH95, from BD Pharmingen) (0.1 Wg/Wl reaction mixture) on ice
for 1 h before the addition of the oligonucleotide probe. The binding
complexes were separated by 6% polyacrylamide gel electrophoresis at
4‡C in 0.5UTBE at 200 V. Gels were then dried and autoradio-
graphed.
The following oligonucleotides were annealed with their comple-
mentary strands, and then used in electrophoretic mobility shift
assays: 375 E2F, 5P-gatcAAGTCTTCCCCGCAAGGCgatc-3P ; 375
E2F-mut, 5P-gatcAAGTCctgatcaaAAGGCgatc-3P ; the high a⁄nity
E2F binding oligonucleotide [17], 5P-CTAGATTTCCCGCGGATC-
3P ; TATA, 5P-GCAGAGCATATAAGGTGAGGTAGGA-3P. Oligo-
nucleotides 375 E2F and 375 E2F-mut contained 18 bp of hPCNA
promoter sequence from 389 to 372 (uppercase letters) with the
potential E2F sites (underlined) or their 8 bp-substituted derivatives
(lowercase letters within the promoter sequence) and 8 bp of unrelated
£anking DNA (lowercase letters).
3. Results
3.1. The activity of the hPCNA promoter is cell
cycle-dependent in L-O2 cells
PCNA synthesis is induced in quiescent cells by stimulation
with serum, growth factors, and adenovirus infection. It £uc-
tuates during the cell cycle [18]. To ¢nd out whether the
hPCNA promoter region functions in the cell cycle-related
transcriptional regulation, we analyzed the reporter expression
directed by wild hPCNA promoter (from 3538 to +60) in
several cell lines, which were synchronously progressing
through the cell cycle, including HeLa, HepG2, MCF-7, and
L-O2, and ¢nally discovered that in L-O2 cultures the activity
of exogenous hPCNA promoter was cell cycle-dependent.
pGL2-hPCNA and pGL2-SV40 constructs were transfected
in asynchronously cycling L-O2 cells. After transfection, the
cells were ¢rst synchronized in G0/G1 by serum starvation for
48 h and subsequently restimulated to enter the cell division
cycle by raising the serum concentration. Cell samples were
harvested at regular intervals after restimulation. Cell cycle
block and re-entry were monitored by FACS analysis. As
shown in Fig. 1A, the ratios between hPCNA promoter ac-
tivity (¢re£y luciferase) and SV40 early promoter activity (Re-
nilla luciferase) were e⁄ciently elevated following serum stim-
ulation, and the highest level was observed 12^15 h after
Table 1
Mutation sites in the hPCNA promoter
Vector Mutation sites Replaced sequence for CTGATCAA Possible binding factor Putative binding sequence of factors
P3509 3516 to 3509 gcggGGGAATGTtaag NF-UB GGGA(A/C)TnYCCC
P3498 3505 to 3498 ttaaGAGGATGAtagg Ets-1 R(G/C)CGGAAGTY
P3342 3349 to 3342 cttgATTTGCATttca Oct-1a ATGCAAAT
P3330 3337 to 3330 ttcaCTTTCACTttcg PRDIa AGTGAAAGTG
P3289 3296 to 3289 gtggGAGGCTGAggag Sp1 GGCGGG
P3216 3223 to 3216 cggaCTTGTTCTgcgg p53a (RRRC(A/T)(T/A)GTTT)X2
P3199 3206 to 3199 cgggTTCAGGAGtcaa RA AGGTCAn2 or 5AGGTCA
P3186 3193 to 3186 caaaGAGGCGGGgaga Sp1a GGCGGG
P3139 3146 to 3139 ttccTCCAATGTatgc CTFa CCAAT
P3122 3129 to 3122 ctagGGGGCGGGcctc Sp1a GGCGGG
P394 3101 to 394 gacaCGATTGGCccta CTFa CCAAT
P375 384 to 377 agtcTTCCCCGCaagg E2F TTTTC(G/C)CG(G/C)
P364 371 to 364 aggcCGTGGGCTggac AP2 CCC(A/C)n(G/C)(G/C)(G/C)
P344 351 to 344 tggtGACGTCGCaacg ATFa TGACGY(C/R)R
P318 325 to 318 tgagAGCGCGCGcttg ^ ^
P+10 +10 to +17 acggTTGCAGGCgtag E2F TTTTC(G/C)CG(G/C)
P+38 +38 to +45 tgtcTTTCTAGGtctc E2F TTTTC(G/C)CG(G/C)
aFactor-related sequence in the hPCNA promoter is equal to its putative binding sequence.
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release, when cells reached S phase (Fig. 1A). The SV40 pro-
moter activity did not signi¢cantly vary in arrested or restimu-
lated cultures (data not shown). Therefore, the up-regulation
of the hPCNA promoter upon entry into S phase was speci¢c.
To assess hPCNA promoter activity during S phase pro-
gression in more detail, L-O2 cells transfected with reporter
constructs were synchronized using the hydroxyurea block/
release protocol. The starting point of administration was
controlled to make sure that the 0 h sample was collected
36 h after transfection. Hydroxyurea is a powerful inhibitor
of DNA replication, and its addition to the culture medium
yields cell populations that are arrested at the G1/S transition.
After removal of the drug, S phase progressed more slowly
than during an ordinary cell cycle [19] ; thus this method of
synchronization enabled us to resolve accurately the progres-
sion through S phase. Luciferase assay con¢rmed that the
hPCNA promoter showed certain activity as early as G1/S
transition (0 h), and continued to increase throughout S phase
(3^12 h after release) (Fig. 1B). Twelve hours after the remov-
al of hydroxyurea when the cells were either in the G2 phase
or entering the mitotic division, hPCNA promoter activity
was drastically decreased. Up-regulation of the hPCNA pro-
moter was speci¢c and was not simply a consequence of re-
sumed transcriptional activity during recovery from the toxic
e¡ects of the hydroxyurea treatment, because the expression
of the pGL2-SV40 construct did not show any signi¢cant
variation during the cell cycle progression (data not shown).
Similarly, transfected cells were synchronized in G2/M by
exposure to nocodazole, whose microtubule-depolymerizing
activity is well established, for 10 h before harvesting. The
nocodazole method enabled us to follow the progression
through the mitotic division. The results indicated that the
activity of the hPCNA promoter was down-regulated during
M phase, and the ratio of hPCNA/SV40 promoter activity
reached the lowest level 6 h later when most cells had com-
pleted their mitotic division and entered a new cell cycle (Fig.
1C). The low level of hPCNA promoter activity did not re£ect
a general toxic e¡ect of the nocodazole treatment, because
SV40 promoter activity was not signi¢cantly decreased at 0 h
or 3 h compared with the level observed 9 h after block release
(data not shown). Due to the half-life of the luciferase (3 h),
all the £uorescence curves were delayed to a certain extent
compared with the corresponding FACS curves.
Together these results indicate that the promoter region
contributes to the cell cycle-dependent transcriptional regula-
tion of the hPCNA gene at least in certain cell lines. In L-O2
cultures, the hPCNA promoter is activated on entry into S
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Fig. 1. Transient expression assays of hPCNA promoter activity
during the cell cycle. The proportions of the cells in corresponding
phases in transfected cultures monitored by FACS are also shown.
The promoter strengths were calculated as ¢re£y/Renilla activity in
each transfected sample. The relative activity at 0 h was taken as 1.
Mean and S.D. values were calculated from at least three indepen-
dent assays. A: The relative activities of the hPCNA promoter in
G0-arrested and restimulated L-O2 cells. B: The relative activities of
the hPCNA promoter in G1/S-arrested and restimulated L-O2 cells.
C: The relative activities of the hPCNA promoter in G2/M-arrested
and released L-O2 cells.
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Fig. 2. Relative activity of wild-type and mutant hPCNA promoter
constructs in asynchronous L-O2 cells. Every PCNA promoter activ-
ity (¢re£y luciferase) was normalized to the SV40 promoter activity
(Renilla luciferase) from the same sample, and the relative activity
of wild hPCNA promoter was taken as 1.
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phase, reaching its maximal transcription in S phase, and is
down-regulated in mitosis.
3.2. Identi¢cation of elements required for optimal activity of
the hPCNA promoter in asynchronously cycling L-O2 cells
To identify the upstream cell cycle regulatory elements, we
¢rst examined the contribution of each putative element sum-
marized in Table 1 to the optimal activity of the hPCNA
promoter in L-O2 cells using transient expression assays. Re-
porter constructs bearing the wild-type hPCNA promoter or
the 8 bp substitution-mutagenized hPCNA promoters and
control construct were transfected into asynchronous L-O2
cells using LipofectAMINE. Thirty-six hours after the trans-
fection, cell lysates were prepared to determine the luciferase
expression level. Every wild or mutant promoter activity (¢re-
£y luciferase) was normalized to the SV40 promoter activity
(Renilla luciferase) from the same sample, and the relative
activity of wild hPCNA promoter was taken as 1. Results in
Fig. 2 show that transcription activities of P3498, P3216,
P3199, P3139, P3122, P394, P375, P364, P344, and
P+38 promoters were drastically reduced compared with the
wild-type promoter. In contrast, transcription activities of the
P3509, P3342, P3330, P3289, P3186, P318, and P+10
constructs were comparable to, or slightly more e⁄cient
than that of the wild-type promoter. Thus, e⁄cient hPCNA
promoter activity in cycling L-O2 cells requires the integrity of
the 3498, 3216, 3199, 3139, 3122, 394, 375, 364, 344,
and +38 sites. The 344 element represents a perfect consensus
site for the transcription factor ATF, which has been well
established [9,10]. The 3216 site was previously demonstrated
to be a DNA damage-responsive element [20]. The 3199,
3122, 394, and 364 sites were also shown to be putative
elements in Tommasi’s in vivo footprinting data [14]. That
is to say, the majority of the essential elements suggested in
Fig. 2 have been described previously, except for the 3498,
3139, 375, and +38 sites.
3.3. A putative E2F site (384 to 375) contributes to cell
cycle-regulated hPCNA transcription
We set out to identify the promoter elements that might be
required for serum responsiveness among all the putative
binding sites summarized in Table 1. Reporter constructs
bearing the wild-type hPCNA promoter or the mutant
hPCNA promoters and pGL2-SV40 control construct were
transfected in L-O2 cells that were then synchronized by se-
rum starvation. G0 and S phase cultures were harvested be-
fore serum addition and 15 h after release respectively. Lucif-
erase assays showed that the activity of the wild-type hPCNA
promoter was low in G0 phase and increased in S phase, and
the 8 bp substitutional mutations did not a¡ect the serum
responsiveness of any of the mutant constructs except P375,
which bears a mutation within the E2F-like site from 384 to
375. As shown in Fig. 3A, the mutation of the 375 E2F
motif abolished the response of the hPCNA promoter to
growth stimulation, and this feature of the site is emphasized
in Fig. 3B. The remaining increasing activity detected could be
due to incomplete cell synchronization. We further examined
the activity of the 375 E2F site-mutated hPCNA promoter
during the cell cycle in L-O2 cells following the protocols used
in Fig. 1A,B. P375 and control constructs were transfected in
L-O2 cultures that were then synchronized by serum starva-
tion and hydroxyurea block respectively. Cell cycle block and
re-entry were monitored by FACS analysis. It was shown that
the ratios between the 375 mutated promoter activity (¢re£y
luciferase) and the SV40 early promoter activity (Renilla lu-
ciferase) were slightly elevated following serum stimulation
(Fig. 4A), and were hardly raised after hydroxyurea block
release (Fig. 4B), substantiating the role of the 375 E2F motif
in cell cycle-related regulation. Together these data indicate
that the E2F motif may contribute to both G1/S and maximal
S phase induction of the hPCNA promoter in synchronized
L-O2 cells. In view of the low degree of cell synchrony (see
Fig. 1), it is likely that the contribution of the 375 E2F
element has been underestimated.
3.4. The putative E2F site (384 to 375) in the hPCNA
promoter shows cell cycle-regulated interaction with DNA
binding factors
Since a group of cell cycle-related genes are regulated by the
E2F family in a coordinate manner [21], the 375 E2F-like site
from 384 to 375 seemed particularly worth investigating. We
then examined the interactions of the oligonucleotide encom-
passing the 375 E2F site with DNA binding factors. In elec-
trophoretic mobility shift assays, two high molecular weight
complexes were formed with the nuclear extracts from asyn-
chronous L-O2 (Fig. 5A, lane 2). The complexes were com-
Fig. 3. Identi¢cation of elements required for serum responsiveness.
A: Relative activity of wild-type and mutant hPCNA promoter con-
structs in growth-arrested (shaded histograms) and S phase-restimu-
lated (open histograms) L-O2 cells. The mean value obtained from
the wild-type promoter in S phase cells was taken as 1. B: Compar-
ison of the ratios between the promoter activities in S phase cells
and in growth-arrested cells.
FEBS 27288 21-5-03
Y.-Y. Li et al./FEBS Letters 544 (2003) 112^118 115
petitively disrupted by excess of the cold 375 E2F oligonu-
cleotide (Fig. 5A, lanes 4 and 5), as well as by the cold E2F
consensus sequence (Fig. 5A, lanes 6 and 7), but not by the
cold mutant 375 E2F oligonucleotide bearing an 8 bp sub-
stitutional mutation which abolishes the E2F binding site
(Fig. 5A, lanes 8 and 9). Thus the 375 E2F site is actually
an E2F binding site, and both of the bands represent E2F-
containing complexes. Interactions established during cell
cycle progression were analyzed using the nuclear extracts
from growth-arrested and S phase L-O2 cells respectively
(Fig. 5B). It is exciting that the electrophoretic mobility shift
pattern of the 375 E2F sequence showed a change between
G0 and S phase cultures. The 375 E2F site formed two com-
plexes with S phase nuclear extracts, whereas the minor band
(both in content and in molecular weight) disappeared when
the nuclear extracts were from growth-arrested cells (Fig. 5B,
lanes 1 and 2), indicating that the minor band represented an
S phase-speci¢c complex. These results did not re£ect a lower
content of transcription factors in extracts from G0, compared
with S phase cells, because the TATA box binding protein had
a comparable abundance in extracts from both sources (Fig.
5B, lanes 3 and 4). The coincidence of S phase-speci¢c E2F
site occupancy and transactivation of the hPCNA promoter
suggests that this complex functions largely as a transcription-
al activator. Formation of the S phase-speci¢c complex was
interfered with by addition of anti-E2F-1 antibody KH95
(Fig. 5A, lane 3), a monoclonal antibody that recognizes an
epitope between amino acids 342 and 386 of human E2F-1
and does not show any cross-reactive properties with other
members of the E2F family [22]. Hence E2F-1, rather than
other members of the E2F family, is the component of the
S phase-speci¢c complex, while the major E2F-containing
Fig. 5. Protein binding features of the 32P-labeled 375 E2F sequence. A: Electrophoretic mobility shift assays of 375 E2F oligonucleotide
alone (lane 1) or incubated with nuclear extracts from asynchronously growing L-O2 cultures (lanes 2^9), which contained no competitor DNA
(lane 2), increasing (50-fold and 100-fold excess) amounts of cold 375 E2F oligonucleotide (wt) (lanes 4 and 5, cold consensus E2F sequence
(cs) (lanes 6 and 7) or cold mutant 375 E2F oligonucleotide (mt) (lanes 8 and 9), as indicated by the triangles at the top of the gel. The aster-
isk (lane 3) represents the interference experiment with anti-E2F-1 antibody. B: Electrophoretic mobility shift assays using extracts from
growth-arrested (lanes 1 and 3) and S phase (lanes 2 and 4) L-O2 cells, with 32P-labeled 375 E2F (lanes 1 and 2) and 32P-labeled TATA (lanes
3 and 4) oligonucleotides. The shifted products are marked by the arrow.
Fig. 4. Transient expression assays of 375 E2F site-mutated hPCNA promoter activity during the cell cycle. The proportions of the cells in
corresponding phases in transfected cultures monitored by FACS are also shown. The promoter strengths were calculated as ¢re£y/Renilla ac-
tivity in each transfected sample. The relative activity at 0 h was taken as 1. Mean and S.D. values were calculated from at least three indepen-
dent assays. A: The relative activities of the 375 mutated promoter in G0-arrested and restimulated L-O2 cells. B: The relative activities of
375 mutated promoter in G1/S-arrested and restimulated L-O2 cells.
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complex (both in content and in molecular weight) was not
interfered with by the anti-E2F-1 antibody (Fig. 5A, lane 3),
suggesting that the E2F member contained in the major com-
plex is not E2F-1.
4. Discussion
PCNA is regulated by a combination of mechanisms that
act at both transcriptional and post-transcriptional levels [8].
It has been reported that introns, rather than the 5P promoter,
may be responsible for cell cycle-regulated hPCNA transcrip-
tion [11,13,14]. However, the data in this work demonstrate
that the activity of the hPCNA promoter £uctuates during
the cell cycle in L-O2 cells. The construct carrying a substitu-
tional mutation in the 375 E2F site showed only 25% as
much transient hPCNA luciferase expression in asynchronous
L-O2 cells as compared with the original pGL2-hPCNA, and
furthermore lost the response to serum stimulation, suggesting
that the putative E2F site 5P-TTCCCCGCAA-3P located at
positions 384 to 375 is required both for optimal promoter
activity and for serum-induced hPCNA transactivation at the
onset of S phase. In electrophoretic mobility shift assays the
32P-labeled 375 E2F sequence formed two high molecular
weight complexes with nuclear extracts from asynchronous
or S phase L-O2 cultures, whereas only the major complex
was seen with G0 extract. Thus the minor complex was the S
phase-speci¢c one. Interference with complex formation by
anti-E2F-1 antibody showed that this complex indeed con-
tains E2F-1. This is the ¢rst demonstration of the E2F site
from 384 to 375 as both a positive regulatory element and a
serum-responsive element in the hPCNA 5P promoter region.
As for the other three elements required for the optimal
activity of hPCNA promoter suggested in Fig. 2, the 3498
site is shown to be a cell type-speci¢c element in our work
(data not shown). Functional analysis of the 3139 site has not
yet been done. The cell type-speci¢c role of the +38 E2F-like
site will be elucidated in another paper (in preparation).
The 375 E2F-like site contains an 8-of-10 match to the
central 10 bp of an inverted repeat E2F element (TTTC/
GCCGCC/GAAA) [23]. It should be noted that some re-
ported E2F sites, such as site 1 of the E1A enhancer [24]
and the dihydrofolate reductase E2F site [25], possess a
dyad symmetry similar to that of the 375 E2F site [23]. An
increasing number of reports document the central role of the
transcription factor E2F in coordinating transcription during
the cell cycle, particularly in the induction of speci¢c genes at
the G1/S transition [21,26]. Although comparison of the
hPCNA promoter with murine, Drosophila, tobacco, and
rice PCNA promoters showed little conservation upstream
of the transcription start site, E2F elements have been char-
acterized in these PCNA genes [14,27^30], indicating that
these E2F elements may be general features of eukaryotic
PCNA genes which fall into the group of G1/S-induced genes
mentioned above. Interestingly, an inverted repeat E2F se-
quence identi¢ed in the tobacco PCNA promoter was located
just from 383 to 374 [28], similar to the 375 E2F site in this
paper, which implies the signi¢cance of the sites in the regu-
lation of the PCNA promoter.
The E2F family comprises six factors related in their DNA
binding speci¢city and expressed at speci¢c phases of the
cycle, and each member can heterodimerize with DP1 or
DP2, giving in all 12 di¡erent DNA binding transcriptional
regulators which function as either transcriptional activators
or repressors, depending on their target genes and the phase
of the cell cycle [21]. In electrophoretic mobility shift assays
two complexes formed between the 375 E2F oligonucleotide
and L-O2 nuclear extracts, and the S phase-speci¢c minor
complex contain E2F-1. It has been well established that
E2F-1 is rapidly transactivated after growth stimulation and
functions as the major activator in late G1/S phase [31].
Therefore, it is likely that this E2F-1-containing complex is
a transcriptional activator in L-O2 cells on entry into S phase,
while the E2F member contained in the major complex is not
E2F-1. The in vitro data showed that the major band did not
vary signi¢cantly between G0 and S phase. Due to the excess
of 32P-labeled oligonucleotide, it seemed that the major com-
plex existed constantly in L-O2 nuclei. Given these ¢ndings,
we propose that the major complex may assume the opposite
responsibility to the minor, and in vivo, where the protein
complexes are dominant, the S phase-speci¢c complex could
competitively bind to the 375 E2F site at the onset of S
phase. The occupancy of E2F sites was initially observed to
be cell cycle-dependent, and functional E2F sites were thought
either to be occupied by free E2F activator only when the
gene was triggered at the G1/S transition [26], or to be bound
by the E2F retinoblastoma repressor only when the gene was
inactive in G0 and G1 phase cells [32]. However, it was later
found that E2F sites can be occupied continuously during the
cell cycle, and thus there may be a switch between a repressing
and an activating complex [14,33]. The data presented here
are consistent with the latter situation, in that the major com-
plex supposed to be a repressor constantly exists in the nuclei,
while the S phase E2F-1-containing complex is observed in
G1/S induction. The identi¢cation of the E2F member con-
tained in the major complex and the other components of the
two complexes, as well as the detailed mechanism involved in
the switch between complexes of di¡erent functions, needs
further investigations. In fact, we could not rule out the pos-
sibility that the major band may include several DNA^protein
complexes because of the complexity of the E2F family and
the associated factors, such as DP and pocket protein family.
It has been proposed by several groups that E2F is involved
in hPCNA regulation during cell cycle progression through an
intron-associated binding site [11^14]. Tommasi et al. showed
that the E2F site located in the ¢rst intron at position +583
plays a role in activation of the hPCNA gene at the onset of
S phase, and their in vivo footprinting data even did not show
the footprint of the 375 E2F site during the cell cycle in
normal human foreskin ¢broblasts (HF39) [14]. In our own
work, the 5P promoter of hPCNA did not respond to serum
stimulation in HeLa, MCF-7, or HepG2 cell lines (data not
shown). It is quite possible that the abundance of E2F-1, or
other factors contained in the S phase-speci¢c complex, is too
low to function in these cell lines, which may be one of the
reasons why other researchers deduced that 5P promoter did
not contribute to S phase induction. In fact, expression of
E2F-regulated genes mostly results from the concerted action
of two E2F elements through the cell cycle [22,25,34]. Thus,
the 375 E2F site, the +583 E2F element, and even other
unknown E2F sites in the hPCNA gene most likely cooperate
to switch the transcription from negative to positive regula-
tion at the onset of S phase, which is consistent with the
observation that the £uctuation range of exogenous hPCNA
promoter activity during the cell cycle was less than that of
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endogenous PCNA synthesis in the parallel experiments (data
not shown), and the coordination model depends on the cell
line and the physiological condition.
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